Copyright © 2024 Research Nester. All Rights Reserved
Thrombopoietin Receptor Agonist Market size was valued at USD 1.74 billion in 2023 and is likely to cross USD 3.95 billion by 2036, expanding at more than 6.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of thrombopoietin receptor agonist is estimated at USD 1.83 billion.
Immune thrombocytopenia purpura is a lethal disease where shortage of platelets could create complications. Thrombopoietin receptor agonists have been pivotal in managing the disease. In the recent times, pharmaceutical companies manufacturing drugs for rare diseases have received approval from European Medicines Agency and the United States Food and Drug Administration. Owing to these factors, the thrombopoietin receptor agonist market is expected to attain a significant CAGR during the forecast period
Growth Drivers
Rising Prevalence of Immune Thrombocytopenia Purpura (ITP)
According to the World Health Organization, the incidence of ITP among adults is estimated to be 32 cases per one million people every year. Increasing prevalence of the disease is projected to drive the thrombopoietin receptor agonist market growth during the forecast period. Frequent awareness activities by ITP support associations in the developed countries have been pivotal in making the masses aware about the disorder which could further fuel the market growth.
Increasing Support from Government Organizations for Medical Treatments
Treatment for immune thrombocytopenia purpura puts a financial burden on the patient and his family. To offset this burden, many governmental organizations and private firms are collaborating proactively to regulate the drug prices and assist the patients and their families. This financial assistance by the government is anticipated to boost the thrombopoietin receptor agonist market growth during the forecast period. Moreover, increasing investments for thrombopoietin receptor agonists research and development in order to invent sophisticated technology that helps in enhancing the drug performance is anticipated to drive the market growth in the coming few years.
Challenges
High Cost of Drug
When the technology involved in developing the thrombopoietin receptor agonists market becomes increasingly advanced, the cost of the drug increases significantly. Further, the cost of the skilled labor involved in developing such technologies may also increase in the coming years which is predicted to affect the market growth during the forecast period.
Stringent Safety Regulations
Thrombopoietin receptor agonists are generally well tolerated by most patients. However, side effects such as headache, fatigue, nausea and aminotransferase are estimated to negatively affect the market growth in future.
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
6.5% |
|
Base Year Market Size (2023) |
USD 1.74 billion |
|
Forecast Year Market Size (2036) |
USD 3.95 billion |
|
Regional Scope |
|
The thrombopoietin receptor agonist market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacy and others, out of which, the hospital pharmacy segment is anticipated to grow at the highest rate on the back of rising number of hospitals across the world.
Our in-depth analysis of the global market includes the following segments:
|
By Agent Type |
|
|
By Distribution Channel |
|
On the basis of regional analysis, the thrombopoietin receptor agonist market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Based on this, the market in North America industry is poised to account for largest revenue share by 2036, attributed to rising awareness of the rare blood disorders, advanced healthcare facilities, easier access to the treatment of ITP and higher investment in research and development activities. In addition, the market in Asia Pacific is expected to record the highest CAGR over the forecast period owing to increasing economic growth and rising awareness of the rare blood disorders among people in the region.
April 30, 2020: Dova Pharmaceuticals, a Swedish company, announced the launch of DOPTELET, a thrombopoietin receptor agonist used for the treatment of immune thrombocytopenia. The product has been granted approval by the China National Medical Products Administration (NMPA) for adult patients with chronic liver disease. The drug was approved based on a double-blind, placebo controlled trial conducted on patients with severe thrombocytopenia and chronic liver disease wherein patients receiving DOPTELET were found to be significantly better than the placebo trial results.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?